首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP
【24h】

Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP

机译:CME-1的离体和体内研究,一种从冬虫夏草菌丝体中纯化的新型多糖,可通过激活腺苷酸环化酶/环状AMP抑制人的血小板活化

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: CME-1, a novel water-soluble polysaccharide, was purified from the mycelia of Cordyceps sinensis, and its chemical structure was characterized to contain mannose and galactose in a ratio of 4:6 (27.6 kDa). CME-1 was originally observed to exert a potent inhibitory effect on tumor migration and a cytoprotective effect against oxidative stress. Activation of platelets caused by arterial thrombosis is relevant to various cardiovascular diseases (CVDs). However, no data are available concerning the effects of CME-1 on platelet activation. Hence, the purpose of this study was to examine the ex vivo and in vivo antithrombotic effects of CME-1 and its possible mechanisms in platelet activation.
机译:简介:一种新型水溶性多糖CME-1,是从冬虫夏草的菌丝体中纯化得到的,其化学结构经表征含有4:6(27.6 kDa)的甘露糖和半乳糖。最初观察到CME-1对肿瘤迁移具有有效的抑制作用,并且对氧化应激具有细胞保护作用。由动脉血栓形成引起的血小板活化与各种心血管疾病(CVD)有关。但是,没有有关CME-1对血小板活化作用的数据。因此,本研究的目的是检查CME-1的离体和体内抗血栓形成作用及其在血小板活化中的可能机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号